Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $20 million, excluding any exercise of the underwriters' option to purchase up to an additional 546,000 shares of common stock. If the underwriters' option is exercised in full, gross proceeds will be approximately $23 million. The offering is expected to close on or about June 24, 2016 subject to customary closing conditions.

Jefferies LLC is acting as sole book-running manager for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.

About Medgenics, Inc.

Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.